Investor Relations

Revance Therapeutics is a biotechnology company developing neuromodulators for use in treating aesthetic and underserved therapeutic conditions, including muscle movement disorders and pain. The company's lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines, cervical dystonia and plantar fasciitis with the potential to be the first long-acting neuromodulator. Revance has developed a proprietary, stabilizing excipient peptide technology designed to create novel, differentiated therapies. The company has a comprehensive pipeline based upon its peptide technology, including injectable and topical formulations of daxibotulinumtoxinA.

More information on Revance may be found at www.revance.com.

NASDAQ | RVNC
34.65
+ 1.90 (+5.80%)
4:00 PM ET on Dec 8, 2017
Delayed at least 20 minutes.

INVESTOR RELATIONS CONTACTS
Jeanie D. Herbert
Sr. Director, Investor Relations
714-325-3584
jherbert@revance.com


Burns McClellan
Ami Bavishi
212-213-0006
abavishi@burnsmc.com

Revance Therapeutics, Inc.
P.O. Box 303
Newark, California 94560-0303
Phone: (510) 742-3400
Fax: (510) 742-3401

Transfer Agent
Computershare
USA
+1 (877) 373 6374
(US, Canada, Puerto Rico)
+1 (781) 575 3120 (non-US)
web.queries@computershare.com

Shareholder Correspondence should be mailed to:
Computershare
P.O. Box 505000
Louisville, KY  40233
 
Shareholder Overnight correspondence should be sent to:
Computershare
462 South 4th Street, Suite 1600
Louisville, KY 40202

Press Releases

Events & Webcasts

Shareholder Tools